Rituximab for Early-Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease

Area of Science:

• Pediatric Rheumatology
• Pulmonology
• Immunology

Background:

• Juvenile dermatomyositis (JDM) is a common childhood inflammatory myopathy.
• JDM-associated interstitial lung disease (JDM-ILD) is a serious complication with limited treatment data.
• Antitranscription intermediary factor 1-gamma antibody (TIF1-γ) positivity is noted in some JDM cases.

Purpose of the Study:

• To report a case of successful early intervention with rituximab in a pediatric patient with severe JDM-ILD.
• To evaluate the safety and efficacy of rituximab as an initial treatment for JDM-ILD.

Main Methods:

• Case report of a three-year-old girl with JDM-ILD.
• Diagnostic workup included physical examination, laboratory tests (LDH, TIF1-γ antibody), whole-body MRI, and HRCT of the chest.
• Treatment involved methylprednisolone, IVIg, methotrexate, and rituximab.

Main Results:

• The patient presented with significant muscle weakness, skin rash, and JDM-ILD (30% lung involvement).
• Rituximab treatment was well-tolerated with no significant adverse events.
• Follow-up showed normalization of muscle strength and improvement in skin and lung manifestations.

Conclusions:

• Rituximab can be considered an effective and safe early intervention for severe, life-threatening JDM-ILD.
• Early use of rituximab may improve outcomes in pediatric patients with JDM-ILD.